Collectively, we reported a novel synergistic immunotherapy strategy by combining tumor specific antigens-based nano-adjuvanted vaccine with PD1 antibody and CD16 CAR-T immune cell treatment for effective targeted anti-tumor immunotherapy. Here, FCGR3A is linked to neoplasm.